Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

10.29
+1.0110.83%
Post-market: 10.290.0050+0.05%19:59 EDT
Volume:31.25M
Turnover:319.67M
Market Cap:10.90B
PE:-10.40
High:10.55
Open:9.39
Low:9.39
Close:9.28
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:2.43
T/O Rate:7.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-10.41
PE(LYR):-26.92

Loading ...

Stock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations

Stock Track
·
May 12

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Simply Wall St.
·
May 11

Immunitybio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Stock Track | ImmunityBio Soars 5.61% Intraday on Positive Analyst Coverage and Buy Rating

Stock Track
·
May 09

Immunitybio Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 09

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)

TIPRANKS
·
May 08

ImmunityBio price target lowered to $12 from $13 at BTIG

TIPRANKS
·
May 08

ImmunityBio (IBRX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 08

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

Benzinga Earnings
·
May 08

UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate

Benzinga Earnings
·
May 07

ImmunityBio faces securities class action after FDA flags misleading promotions; shares fall 21%

Reuters
·
May 07

ImmunityBio Q1 net loss widens to $632.8 million; revenue more than doubled to $44.2 million

Reuters
·
May 07

Immunitybio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7X Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

THOMSON REUTERS
·
May 07

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 06

ImmunityBio presents new ANKTIVA+BCG comparative data in NMIBC CIS at AUA 2026

Reuters
·
May 05

A Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth

Simply Wall St.
·
May 03

ImmunityBio faces shareholder class action over alleged ANKTIVA promotion misstatements

Reuters
·
Apr 30

ImmunityBio announces annual shareholder meeting

Reuters
·
Apr 30

H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)

TIPRANKS
·
Apr 30

Does ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?

Simply Wall St.
·
Apr 28